Gland Pharma Share Price Swings After Q4 Earnings

Gland Pharma's share price experienced notable volatility following the release of its fourth quarter earnings report. Initially, the stock declined by 2.81% at market open, but later recovered to trade 3.78% higher.

The company's revenue fell by 7.3% to Rs 1,425 crore, compared to Rs 1,537 crore in the same period last year. This was below Bloomberg's estimate of Rs 1,552 crore.

Ebitda saw a slight decline of 0.7%, reaching Rs 347.4 crore versus Rs 350 crore previously. Bloomberg had estimated Ebitda to be Rs 376 crore. The Ebitda margin improved to 24.4% from 22.8%, surpassing Bloomberg's estimate of 24.2%.

Net profit decreased by 3.1% to Rs 186 crore, down from Rs 192 crore. This was significantly lower than Bloomberg's estimate of Rs 233 crore. Ebitda remained flat due to a 6% increase in employee expenses.

The scrip rose as much as 3.78% to Rs 1,554.90 apiece. It pared gains to trade 3.45% higher at Rs 1,550 apiece, as of 09:32 a.m. This compares to a 0.22% advance in the NSE Nifty 50.

It has fallen 13.93% in the last 12 months. Total traded volume so far in the day stood at 1.1 times its 30-day average. The relative strength index was at 68.

Out of 15 analysts tracking the company, eight maintain a 'buy' rating, one recommends a 'hold' and six suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 10.3%.